Integra LifeSciences (IART) Set to Announce Quarterly Earnings on Monday

Integra LifeSciences (NASDAQ:IART) is scheduled to be posting its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect Integra LifeSciences to post earnings of $0.55 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. During the same quarter in the previous year, the company earned $0.94 earnings per share. Integra LifeSciences’s quarterly revenue was down .3% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

Shares of IART opened at $28.89 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 1 year low of $27.18 and a 1 year high of $51.12. The firm has a fifty day moving average of $34.07 and a 200-day moving average of $38.51. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 0.88 and a beta of 1.17.

Analyst Ratings Changes

Several research analysts have commented on the stock. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. JMP Securities dropped their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Truist Financial cut their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and an average target price of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.